HomeScienceResearchers Identify New Mutational Si
SCIENCE

Researchers Identify New Mutational Signature in Colorectal Cancer

An analysis of 2,616 colorectal tumors revealed a distinct mutational signature designated SBS111 that was previously missed in DNA repair-proficient cancers.

WHAT YOU NEED TO KNOW
  • Analysis of 2,616 colorectal cancers across three cohorts confirmed the presence of signature SBS_D.
  • SBS_D was submitted to the COSMIC database under the provisional designation SBS111.
  • Computational analyses ran on the Triton Shared Computing Cluster at UC San Diego.

Researchers identified a distinct mutational signature in colorectal cancer that previous genomic analyses had missed, according to a study published in Nature Communications. The signature, named SBS_D, appeared consistently across an evaluation of 2,616 colorectal cancers drawn from three independent patient cohorts.

The team re-evaluated earlier work on 802 microsatellite-stable colorectal cancers where SBS_D had initially been decomposed into the known signature SBS18. The new evaluation showed that SBS_D represents a separate biological process. While its pattern resembles signatures linked to DNA repair deficiencies, the researchers found no evidence that canonical defects in those repair pathways cause it. Instead, the authors proposed that the signature arises from DNA repair infidelity developing late in tumor progression within DNA repair-proficient tumors.

The researchers submitted SBS_D to the COSMIC database, which assigned it the provisional designation SBS111. The study utilized genomic data generated in part by the TCGA Research Network and ran computational workloads on the Triton Shared Computing Cluster at the San Diego Supercomputer Center of the University of California San Diego.

Mariya Kazachkova and Ludmil B. Alexandrov of UC San Diego authored the study alongside collaborators from the Wellcome Sanger Institute, the International Agency for Research on Cancer, and the University of Manchester. The research received support through the Cancer Grand Challenges Mutographs team funded by Cancer Research UK, alongside grants from the US National Institutes of Health.

Xentir Media
Xentir Media NewsroomSource-backed AI and technology coverage, drafted by Xentir's automated editorial system under fixed human-set rules. See our editorial policy and AI usage policy.
J
Jomon · Founder & EditorFounder and editor of Xentir Media. Sets the editorial rules the newsroom system runs under, and is accountable for its corrections. About Jomon · [email protected]
The Xentir Brief
The developments worth knowing — one useful email.
Get the Brief →